Philippines' Marcos Keeps Economic Team Amid Cabinet Shakeup
Philippine President Ferdinand Marcos Jr. retained Ralph Recto as his finance chief and the rest of his economic team amid a Cabinet revamp, signaling continuity in his economic agenda.
Recto will keep his post, Executive Secretary Lucas Bersamin said in a briefing on Friday. The ministers for trade, economic planning and budget will also stay on, he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
2 hours ago
- Bloomberg
US Will Not Give Vietnam Reprieve on Tariffs, Lutnick Says
Washington will not reciprocate even if Hanoi removes all tariffs on American goods, according to US Secretary of Commerce Howard Lutnick, as he said Vietnam re-exports a significant volume of Chinese products to the US. 'Absolutely not, absolutely not. That would be the silliest thing we could do,' Lutnick said when Republican Senator John Kennedy asked him whether the US will respond in kind if Vietnam decides to eliminate all tariffs and trade barriers against American imports, and calling a potential agreement like that 'a terrible deal.'
Washington Post
2 hours ago
- Washington Post
Vietnam drops two-child policy amid demographic fears
Vietnam on Tuesday scrapped its nearly four-decade policy limiting families to two children, as Vietnamese birth rates continue to drop, the aging population increases and officials warn of long-term risks of demographic decline for the economy, defense and the fabric of society. The National Assembly removed a clause in the country's population ordinance that says parents should have 'one or two children' except in government-approved 'special cases,' state-run media reported.
Yahoo
3 hours ago
- Yahoo
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /CNW/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key step in Continuity's strategy to become a leader in device targeted therapeutics for intractable solid tumors. Founded by leading scientists and clinicians, Focal Medical has developed a proprietary platform that delivers chemotherapy directly to tumors using iontophoresis—this minimally-invasive technique utilizes a mild electrical current to drive therapeutic compounds into targeted tissues. This method enhances local drug concentration while minimizing systemic toxicity, a critical need in the treatment of pancreatic and other solid-tissue cancers. Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year. "This is a transformative milestone for Continuity Biosciences," said Ramakrishna Venugopalan, PhD, MBA, Chief Executive Officer of Continuity Biosciences. "Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic." Through the acquisition, Continuity Biosciences obtains Focal Medical's entire patent estate, iontophoresis technology platform and specialized equipment, scientific know-how, and licensing agreements with the University of North Carolina at Chapel Hill. In addition, key scientific staff and leadership from Focal will join Continuity, further enhancing its internal capabilities. A dedicated research and development facility in Cary, NC that supports ongoing platform and pipeline advancement is also part of the acquisition and will be expanded to support other delivery platforms. Visionary Founders Driving the Innovation Focal Medical was co-founded by: Jen Jen Yeh, MD, a surgical oncologist and professor at UNC-Chapel Hill with joint appointments in Surgery and Pharmacology. She serves as assistant dean of translational research in UNC School of Medicine and associate director of translational research in UNC Lineberger Comprehensive Cancer Center. Dr. Yeh is widely recognized for her expertise in pancreatic cancer and translational oncology. Joseph DeSimone, PhD, an award-winning chemist, entrepreneur, and academic, currently serving as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. He is globally known for his breakthroughs in materials science, nanomedicine, and advanced manufacturing, including 3D printing. Their iontophoresis system is designed to deliver gemcitabine, an FDA-approved chemotherapy agent, directly into pancreatic tumors. Traditional systemic administration of gemcitabine is often limited by poor tumor penetration and significant toxicity. Focal's approach bypasses those limitations by delivering the drug directly to the tumor site with high precision and minimal systemic toxicity. "After nearly a decade of R&D, we are excited to join the Continuity Biosciences family," said Tony Voiers, Acting CEO of Focal Medical. "We are grateful to our founders, scientific collaborators, and investors who have helped us reach this pivotal point. Partnering with Continuity ensures that this novel therapy moves forward into the clinic where it has the potential to help patients facing one of the deadliest cancers." This acquisition reinforces Continuity Biosciences' commitment to building a diverse portfolio of clinically meaningful drug delivery platforms and signals a decisive move toward becoming a clinical-stage leader in site-specific therapy. About Continuity BiosciencesContinuity Biosciences, LLC is a biopharmaceutical company developing advanced drug delivery technologies that address the limitations of conventional therapeutic administration. With operations in Bradenton, FL; Houston, TX; Raleigh, NC; and Torino, Italy, the company focuses on combination drug-device platforms for chronic and complex About Focal MedicalFocal Medical, Inc. develops energy-based chemotherapy delivery systems that enable direct application of drugs to tumor sites. Its mission is to improve efficacy and reduce toxicity in the treatment of solid tumors, with an initial focus on pancreatic View original content to download multimedia: SOURCE Continuity Biosciences LLC View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
